Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc.: Federal Circuit Limits Attempts to Restart Mandatory Patent Litigation Stay Deadlines
Patent disputes involving pharmaceutical products often require companies to navigate multiple legal proceedings at the same time. A brand-name pharmaceutical company may pursue patent enforcement before the International Trade Commission (“ITC”), while a competing company may seek relief through a federal district court action challenging the same patents. When these proceedings overlap, parties must carefully evaluate not only their substantive patent arguments but also the procedural rules governing timing, jurisdiction, and litigation strategy.
The Federal Circuit’s decision in Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc. addressed one of these important procedural questions. The case examined whether a party could voluntarily dismiss a declaratory judgment action and later file a substantially identical lawsuit in order to obtain a new opportunity to request a mandatory stay under 28 U.S.C. § 1659. The Federal Circuit held that it could not. The court concluded that a litigant cannot reset the statutory deadline for seeking a mandatory stay by voluntarily dismissing and refiling essentially the same action.
Although the dispute involved a specific pharmaceutical patent controversy, the decision has broader implications for companies involved in complex intellectual property litigation. The ruling provides important guidance regarding the interaction between:
Parallel ITC investigations and district court litigation.
Declaratory judgment actions involving patent rights.
The timing requirements for seeking mandatory stays.
The consequences of voluntary dismissal and refiling.
Strategic considerations in multi-forum patent disputes.
The decision is particularly significant for pharmaceutical and biotechnology companies because patent disputes in those industries frequently involve overlapping proceedings that can determine whether competing products may enter the marketplace, whether patent rights remain enforceable, and how long regulatory exclusivity may continue.
Ultimately, Ascendis Pharma reinforces a broader principle of federal litigation: procedural mechanisms intended to promote efficiency must be applied consistently with the statutory limits established by Congress.
The Intersection of Pharmaceutical Patents, ITC Proceedings, and Federal Court Litigation
The pharmaceutical industry relies heavily on patent protection because patents can provide innovators with periods of exclusivity that help companies recover the substantial costs associated with discovering, developing, testing, and obtaining regulatory approval for new therapies.
However, pharmaceutical patent disputes are often more complicated than traditional patent cases because timing is critical. A competitor’s ability to launch a product may depend on whether asserted patents are valid and enforceable, whether infringement exists, and whether litigation affects the timing of market entry.
Companies involved in pharmaceutical patent disputes frequently pursue litigation in multiple forums. One important forum is federal district court. Federal courts can resolve patent validity, infringement, and claim construction disputes and may award remedies such as:
Monetary damages
Injunctions
Declaratory judgments
Other forms of equitable relief
Another important forum is the ITC. The ITC investigates allegations of unfair trade practices involving imported goods under Section 337 of the Tariff Act of 1930. Patent owners often seek ITC investigations because the agency can provide powerful exclusionary remedies, including orders preventing infringing products from entering the United States.
Unlike district courts, the ITC does not typically award damages. Instead, its primary remedies involve excluding infringing products from importation. As a result, companies often consider ITC proceedings and district court litigation together when developing patent enforcement and defense strategies.
Because district courts and the ITC may address similar patent issues, Congress created mechanisms to coordinate these proceedings. One of those mechanisms is 28 U.S.C. § 1659, which requires a district court to stay certain proceedings upon request when the case involves issues also pending before a related ITC investigation. The dispute in Ascendis Pharma centered on whether that statutory stay provision could be invoked again after a party dismissed one lawsuit and later filed another.
Key Legal Concepts in Ascendis Pharma
A declaratory judgment action allows a party to ask a court to resolve legal uncertainty before facing traditional enforcement litigation. In patent cases, companies often file declaratory judgment actions when they believe they face a credible threat of infringement litigation or need certainty regarding their ability to market a product. A company may seek a declaration holding that:
A patent is invalid.
A product does not infringe.
A patent owner cannot prevent commercial activity based on the asserted patent rights.
The Declaratory Judgment Act, 28 U.S.C. §§ 2201–2202, gives federal courts authority to issue such declarations when an actual controversy exists. The Supreme Court has explained that courts cannot issue advisory opinions based on hypothetical disputes. Instead, there must be a real and substantial controversy between parties with adverse legal interests.
The modern standard for declaratory judgment jurisdiction was shaped by decisions such as MedImmune, Inc. v. Genentech, Inc., in which the Supreme Court recognized that a party may seek declaratory relief even when it has not yet been sued for patent infringement. In pharmaceutical litigation, declaratory judgment actions are often strategically important because they allow companies to seek early resolution of patent disputes that may affect product launches and market competition.
What Is a Section 1659 Mandatory Stay?
The central statutory provision in Ascendis Pharma was 28 U.S.C. § 1659. Section 1659 addresses situations where a federal district court action involves issues that are also being investigated in a related ITC proceeding involving the same parties.
The statute allows a party to request a stay, and when the statutory requirements are satisfied, the district court must stay the proceedings until the ITC investigation is completed. The purpose of the statute is to promote efficiency by preventing unnecessary duplication between parallel ITC and district court proceedings. Without a stay mechanism, companies could be forced to conduct duplicative litigation involving:
Similar discovery requests
Similar claim construction issues
Similar invalidity arguments
Similar infringement questions
A stay can reduce costs and prevent inconsistent decisions between two different proceedings. However, Section 1659 contains timing requirements. A party must request the stay within a specific period after receiving notice of the district court action. The issue in Ascendis Pharma was whether a party could effectively restart that clock by dismissing its lawsuit and filing a new one.
The Dispute Between Ascendis Pharma and BioMarin
The litigation arose from a broader patent dispute involving pharmaceutical technology, intellectual property rights, and competing commercial interests between the two named companies.
BioMarin initiated an investigation before the ITC asserting patent-related claims against Ascendis. Because, as noted above, ITC investigations and district court actions may address overlapping patent issues, the existence of the investigation created the potential for parallel litigation. Ascendis later filed a declaratory judgment action in federal district court involving related patent issues.
After filing the lawsuit, Ascendis voluntarily dismissed the action without prejudice. A voluntary dismissal without prejudice generally allows a plaintiff to refile claims because the dismissal does not constitute a decision on the merits.
Ascendis subsequently filed a new declaratory judgment action addressing substantially the same underlying patent dispute. Following the refiling, Ascendis sought a mandatory stay under Section 1659. The district court rejected the request, concluding that Ascendis could not create a new statutory deadline for seeking a Section 1659 stay by voluntarily dismissing and refiling the action. Ascendis appealed the decision to the Federal Circuit.
The central question before the appellate court was whether a party could create a new Section 1659 stay deadline by voluntarily dismissing and refiling an essentially identical declaratory judgment action. The Federal Circuit concluded that the answer was no.
The Federal Circuit’s Decision and Reasoning
The Federal Circuit affirmed the district court’s ruling and held that Ascendis could not restart the Section 1659 deadline by voluntarily dismissing its action and later refiling the dispute. The court’s reasoning focused on the purpose and structure of the statute.
Section 1659 was designed to provide a mechanism for coordinating parallel litigation, not to create repeated opportunities to obtain a stay after statutory deadlines have expired. The court explained that allowing a party to restart the statutory deadline through dismissal and refiling would undermine the predictability Congress intended when establishing the stay procedure.
A contrary interpretation could encourage procedural strategies that would allow parties to repeatedly reset statutory deadlines. For example, a party could:
File a declaratory judgment action.
Wait until the deadline to request a stay approaches.
Voluntarily dismiss the action.
Refile the same lawsuit.
Seek a new stay period.
The Federal Circuit rejected this approach because it would effectively give parties repeated opportunities to obtain a mandatory stay that Congress tied to a specific statutory deadline. The court emphasized that procedural rules must be applied in a manner consistent with their purpose. A voluntary dismissal may terminate a lawsuit, but it does not necessarily erase the history of the litigation or allow a party to avoid previously applicable procedural deadlines.
Why the Court’s Holding Matters for Patent Litigation Strategy
The decision is important because pharmaceutical companies often make strategic decisions based on procedural timing. Patent litigation strategy may involve questions such as:
Whether to file a declaratory judgment action
Whether to request a stay
Whether to pursue parallel ITC proceedings
Whether to challenge patents before product launch
Whether to seek early judicial resolution
After Ascendis Pharma, parties involved in parallel patent litigation must carefully consider the consequences of dismissing and refiling an action when statutory deadlines may apply. A voluntary dismissal may have strategic consequences beyond simply ending the case. Companies cannot assume that refiling a lawsuit will restore procedural rights that have already expired. This is especially important in pharmaceutical and biotechnology industries, where litigation timing can directly affect product launches, market entry, and competitive strategy. For pharmaceutical companies, months of litigation delay or acceleration can affect:
Product launch schedules
Market exclusivity periods
Investment decisions
Licensing negotiations
Competitive positioning
The Continuing Impact of Ascendis Pharma
Ascendis Pharma is an important reminder that successful patent litigation strategy requires more than strong substantive arguments. Companies must also understand the procedural framework governing how and when courts will consider those arguments.
The Federal Circuit’s decision establishes that parties cannot use voluntary dismissal and refiling as a mechanism to reset the statutory deadline for seeking a mandatory stay under Section 1659. For pharmaceutical companies, biotechnology firms, and other businesses involved in complex intellectual property disputes, the ruling highlights the importance of early planning and coordinated litigation strategies.
The case also illustrates a broader principle in federal litigation: procedural rules exist to create predictability and fairness. Parties may make strategic decisions within those rules, but procedural mechanisms must operate within the limits established by Congress. As pharmaceutical patent disputes continue to involve multiple forums, including parallel proceedings before federal courts and the ITC, decisions like Ascendis Pharma will remain significant for companies seeking to protect intellectual property rights, challenge competitor patents, and manage litigation risk.
If you’re interested in learning more about this topic or how the principles discussed in this article may impact your business, don’t hesitate to contact us at info@patentxl.com or at +1(610)871-2024.
